Monitoring Weight Loss in Pediatric Patients Taking Extended-Release Stimulants for ADHD: In Conversation With Stephen Mateka, DO
Key Takeaways: The FDA updated labels for extended-release ADHD stimulants, highlighting weight loss risks in children under six due to higher plasma exposure and adverse effects. Clinicians should update informed consent discussions and adjust dosages for young patients, considering the new risk-benefit ratio. Weight monitoring should follow second-generation antipsychotic guidelines, with regular checks and parental input. Alternatives to extended-release stimulants include increased dosing frequency of immediate-release formulations and FDA-approved medications like atomoxetine and guanfacine extended-release.
Other Articles in this Edition
Study finds no link between aluminum in vaccines and autism, asthma
Can’t sleep, can’t focus, can’t thrive? ADHD and insomnia may be a vicious cycle
Methylphenidate: ADHD drug curbs impulsivity in men only, linked to brain wiring differences
Significant Sensory Processing Differences Found in ADHD Patients
Treatment Adherence Challenges in ADHD
People with ADHD exhibit altered brain activity before making high-stakes choices
MRI study reveals structural brain changes in children with restrictive eating disorders
Ultra-processed foods threaten brain health in kids and teens, review warns
Short videos, long questions: Is there any link with children’s attention?
The Importance of Managing Screen Exposure with Matthew Roe, OD